Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Compass01:23

Compass

3.1K
The compass is a fundamental instrument that operates by aligning its magnetic needle with Earth's magnetic field. This alignment facilitates navigation and orientation, offering a means to determine direction relative to magnetic north. However, the magnetic needle points to magnetic north, which differs slightly from true geographic north due to magnetic declination, which is the angular deviation between these two points. Declination varies based on geographic location and shifts over time...
3.1K
Clinical Trials01:16

Clinical Trials

10.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Pharmacovigilance01:19

Pharmacovigilance

1.5K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is there a beneficial dose of alcohol?

Casopis lekaru ceskych·2026
Same author

Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney.

Blood pressure·2024
Same author

Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.

Journal of hypertension·2024
Same author

Identification of Plasmatic MicroRNA-206 as New Predictor of Early Recurrence of Atrial Fibrillation After Catheter Ablation Using Next-generation Sequencing.

Molecular diagnosis & therapy·2024
Same author

In the prevention of dementia, the focus should be on early and consistent treatment of hypertension.

Vnitrni lekarstvi·2023
Same author

Polymorphism rs7079 in miR-31/-584 Binding Site in Angiotensinogen Gene Associates with Earlier Onset of Coronary Artery Disease in Central European Population.

Genes·2022

Related Experiment Video

Updated: Dec 7, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K

Rivaroxaban in COMPASS trial.

Filip Šustr, Miroslav Souček

    Vnitrni Lekarstvi
    |September 25, 2020
    PubMed
    Summary

    Secondary prevention of cardiovascular diseases (CVD) is crucial. The COMPASS trial found that combining rivaroxaban with acetylsalicylic acid effectively prevents CVD progression and relapse in patients.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Public Health

    Background:

    • Cardiovascular diseases (CVD) are the leading cause of mortality in Europe.
    • Effective secondary prevention strategies are essential to combat high CVD mortality rates.
    • Antithrombotic treatment is considered the gold standard for secondary CVD prevention.

    Purpose of the Study:

    • To evaluate the effectiveness of rivaroxaban in secondary prevention of CVD.
    • To assess the combined efficacy of rivaroxaban and acetylsalicylic acid in CVD patients.

    Main Methods:

    • The study focused on the COMPASS trial.
    • Investigated the use of rivaroxaban as a secondary prevention therapy for CVD.
    • Analyzed patient outcomes related to disease progression and relapse.
    Keywords:
    ASACOMPASScoronary artery diseaserivaroxaban

    More Related Videos

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
    10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    17.7K
    Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
    06:04

    Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

    Published on: August 8, 2025

    420

    Related Experiment Videos

    Last Updated: Dec 7, 2025

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
    11:17

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

    Published on: October 12, 2012

    14.2K
    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
    10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    17.7K
    Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
    06:04

    Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

    Published on: August 8, 2025

    420

    Main Results:

    • The COMPASS trial demonstrated positive outcomes for rivaroxaban use in CVD secondary prevention.
    • Combining rivaroxaban with acetylsalicylic acid showed significant benefits.
    • This combination therapy aids in preventing the progression or relapse of cardiovascular diseases.

    Conclusions:

    • Rivaroxaban, particularly in combination with acetylsalicylic acid, is a highly effective option for secondary CVD prevention.
    • This therapeutic approach offers a promising strategy to reduce CVD-related mortality and morbidity.